Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

PURPOSE: The Wee1 kinase inhibitor adavosertib abrogates cell cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase 2 dose (RPh2D). Here, we report results for once-daily adavosertib. PATIENTS AND METHODS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Takebe, Naoko, Naqash, Abdul Rafeh, Coyne, Geraldine O’Sullivan, Kummar, Shivaani, Do, Khanh, Bruns, Ashley, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Piekarz, Richard, Sharon, Elad, Streicher, Howard, Mittra, Arjun, Miller, Sarah B., Ji, Jiuping, Wilsker, Deborah, Kinders, Robert J., Parchment, Ralph E., Chen, Li, Chang, Ting-Chia, Das, Biswajit, Mugundu, Ganesh, Doroshow, James H., Chen, Alice P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282703/
https://ncbi.nlm.nih.gov/pubmed/33863809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-21-0329
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados